HC Wainwright Predicts Evotec’s Q1 Earnings (NASDAQ:EVO)

Evotec AG (NASDAQ:EVO) – Research analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Evotec in a research report issued on Friday, August 14th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings of ($0.01) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Evotec’s Q2 2027 earnings at $0.00 EPS, Q3 2027 earnings at $0.02 EPS, Q4 2027 earnings at $0.03 EPS, FY2027 earnings at $0.04 EPS and FY2028 earnings at $0.32 EPS.

Several other analysts have also weighed in on EVO. TD Cowen lowered Evotec from a “buy” rating to a “hold” rating and set a $2.00 price objective for the company. in a report on Wednesday, July 15th. Wall Street Zen downgraded Evotec from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evotec in a report on Tuesday, July 21st. Finally, Berenberg Bank lowered Evotec from a “buy” rating to a “hold” rating in a research report on Thursday, July 16th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $3.00.

Evotec Stock Performance

Shares of EVO stock opened at $1.96 on Monday. The company has a quick ratio of 2.21, a current ratio of 2.33 and a debt-to-equity ratio of 0.62. Evotec has a one year low of $1.90 and a one year high of $4.27. The company’s 50-day simple moving average is $2.36 and its 200-day simple moving average is $2.79.

Institutional Investors Weigh In On Evotec

Several large investors have recently added to or reduced their stakes in EVO. Optiver Holding B.V. lifted its stake in Evotec by 598.4% in the first quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock valued at $709,000 after buying an additional 242,973 shares during the last quarter. WCM Investment Management LLC grew its position in shares of Evotec by 12.1% during the first quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock worth $1,480,000 after acquiring an additional 67,917 shares during the last quarter. Apollon Wealth Management LLC bought a new position in shares of Evotec during the first quarter worth about $28,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Evotec in the 1st quarter worth about $44,000. Finally, XTX Topco Ltd increased its holdings in shares of Evotec by 25.1% in the 4th quarter. XTX Topco Ltd now owns 18,469 shares of the company’s stock worth $57,000 after acquiring an additional 3,709 shares during the period. 5.81% of the stock is owned by institutional investors and hedge funds.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.